Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo
Company profile
Ticker
SNY
Exchange
Website
CEO
Olivier Brandicourt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SANOFI SYNTHELABO SA, SANOFI-AVENTIS
SEC CIK
Corporate docs
IRS number
133529324
SNY stock data
Latest filings (excl ownership)
6-K
Sales growth of 6.7% at CER and business EPS(1) of €1.78
25 Apr 24
F-3ASR
Automatic shelf registration (foreign)
4 Apr 24
S-8
Registration of securities for employees
4 Apr 24
6-K
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
20 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Mar 24
6-K
Current report (foreign)
27 Feb 24
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
23 Feb 24
6-K
Current report (foreign)
15 Feb 24
6-K
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
2 Feb 24
6-K
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
1 Feb 24
Latest ownership filings
SC 13G/A
Amundi
14 Feb 24
SC 13G/A
DODGE & COX
13 Feb 24
SC 13G/A
BlackRock Inc.
6 Feb 24
SC 13G
MeiraGTx Holdings plc
6 Nov 23
11-K
Annual report of employee stock purchases
28 Jun 23
11-K
Annual report of employee stock purchases
28 Jun 23
SC 13G/A
DODGE & COX
14 Feb 23
SC 13G/A
Amundi
10 Feb 23
SC 13G/A
BlackRock Inc.
7 Feb 23
11-K
Annual report of employee stock purchases
29 Jun 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
9.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 667 |
Opened positions | 69 |
Closed positions | 45 |
Increased positions | 262 |
Reduced positions | 200 |
13F shares | Current |
---|---|
Total value | 13.42 tn |
Total shares | 250.33 mm |
Total puts | 1.24 mm |
Total calls | 1.45 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Dodge & Cox | 78.51 mm | $4.21 tn |
FMR | 22.80 mm | $1.22 tn |
Fisher Asset Management | 14.94 mm | $801.53 bn |
Boston Partners | 12.79 mm | $680.70 bn |
BAC Bank Of America | 10.58 mm | $567.73 bn |
BLK Blackrock | 9.81 mm | $526.02 bn |
MS Morgan Stanley | 7.32 mm | $392.80 bn |
IVZ Invesco | 6.83 mm | $366.42 bn |
BK Bank Of New York Mellon | 5.65 mm | $303.10 bn |
Nuveen Asset Management | 4.20 mm | $225.19 bn |
News
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
25 Apr 24
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
25 Apr 24
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
25 Apr 24
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
25 Apr 24
Sanofi Reiterates 2024 Business EPS Guidance, Expects It To Remain Roughly Stable; Applying Average April 2024 Exchange Rates, The Currency Impact Is Estimated To Be Between -5.5% And -6.5%
25 Apr 24
Press releases
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
10 Feb 24
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
6 Feb 24